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Background: Blood Pressure related disease affected 118 million people in India in the year 2000; this figure will
double by 2025. Around one in four adults in rural India have hypertension, and of those, only a minority are
accessing appropriate care. Health systems in India face substantial challenges to meet these gaps in care, and
innovative solutions are needed.
Methods: We hypothesise that a multifaceted intervention involving capacity strengthening of primary healthcare
doctors and non-physician healthcare workers through use of a mobile device-based clinical decision support
system will result in improved blood pressure control for individuals at high risk of a cardiovascular disease event
when compared with usual healthcare. This intervention will be implemented as a stepped wedge, cluster
randomised controlled trial in 18 primary health centres and 54 villages in rural Andhra Pradesh involving adults
aged ≥40 years at high cardiovascular disease event risk (approximately 15,000 people). Cardiovascular disease
event risk will be calculated based on World Health Organisation/International Society of Hypertension’s
region-specific risk charts. Cluster randomisation will occur at the level of the primary health centres. Outcome
analyses will be conducted blinded to intervention allocation.
Expected outcomes: The primary study outcome is the difference in the proportion of people meeting
guideline-recommended blood pressure targets in the intervention period vs. the control period. Secondary
outcomes include mean reduction in blood pressure levels; change in other cardiovascular disease risk factors,
including body mass index, current smoking, reported healthy eating habits, and reported physical activity levels;
self-reported use of blood pressure and other cardiovascular medicines; quality of life (using the EQ-5D); and
cardiovascular disease events (using hospitalisation data). Trial outcomes will be accompanied by detailed process
and economic evaluations.
Significance: The findings are likely to inform policy on a scalable strategy to overcome entrenched inequities in
access to effective healthcare for under-served populations in low and middle income country settings.
Trial registration: Clinical Trial Registry India CTRI/2013/06/003753.
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Cardiovascular disease (CVD) burden in India
In India, the number of years of life lost due to CVD
deaths among populations 35 to 64 years of age will in-
crease from 9.2 million in 2000 to 17.9 million in 2030 –
more life years lost than is projected for China, Russia,
and the USA combined [1]. Elevated blood pressure (BP)
is a major contributor to the increasing burden of CVD
in India, estimated to be responsible for a million deaths
annually [2]. India had an estimated 118 million people
diagnosed with hypertension in 2000 with projections
indicating a near doubling to 213 million by 2025 [3].
Around 16% of ischaemic heart disease, 21% of periph-
eral vascular disease, 24% of acute myocardial infarc-
tions, and 29% of strokes in India are considered
attributable to hypertension [4]. This disease burden is
not confined to urban India. In rural areas, where 70%
of the country’s population resides, high levels of hyper-
tension and other CVD risk factors exist, with CVD
already the leading cause of adult death in many such
communities [5,6].
Evidence-practice gaps in CVD prevention
Use of BP lowering treatments in rural India is limited,
even where mandated low cost drugs are available in
government formularies. Earlier studies done in rural
communities in India have shown that few people with
hypertension and/or CVD are appropriately managed
[7,8]. In rural Andhra Pradesh, 27.0% of adults aged
≥30 years had hypertension with around one-half previ-
ously unidentified [6,8-10]. In these communities, 7.7%
of adults had established CVD, and a further 8.1% had a
10-year CVD risk ≥ 30%. For those with CVD, 25% had
non-optimal BP levels (systolic BP >140 mmHg). For
those at high risk without known CVD, 95% had non-
optimal BP levels. These rates were similarly experienced
by men and women. Overall, only 39% of all high risk in-
dividuals with or without CVD have adequate BP con-
trol, indicating large evidence-practice gaps. In the
context of limited resources, prioritising high-risk pa-
tients for BP lowering treatment is likely to be a highly
cost-efficient approach and is consistent with Indian
guideline recommendations.
Workforce challenges
India’s health system faces great challenges in tackling a
rapidly escalating burden of CVD. Key issues include
lack of healthcare facilities, limited access to healthcare
providers, and high out-of-pocket costs for consumers
[11]. It is therefore imperative that innovative solutions
are developed to address these issues. India’s three tier
healthcare system provides nurse/midwife level primary
healthcare at the sub-centre (population approximately
3,000 to 5,000), doctor-level care at the Primary HealthCentre (PHC) (population approximately 20,000 to
30,000), and specialised care at the Community Health-
care Centres (population approximately 80,000 to
120,000). The PHC, which is usually led by one doctor,
is expected to provide comprehensive primary health-
care for up to 30,000 residents. This leads to consider-
able strain on PHC resources potentially resulting in
inadequate quality of care.
In this context, there is an urgent need for innovations
in healthcare delivery. One promising strategy involves
‘task shifting,’ where front-line, non-physician health
workers are delegated some of the tasks traditionally
performed by physicians. In the setting of HIV/AIDS
care, task-shifting has been shown to improve health
outcomes and processes of care [12]. In India, there is
some evidence that task shifting CVD risk assessment to
non-physician health workers via a simple algorithm can
increase the detection of CVD [13]. An example of
front-line health workers in India is Accredited Social
Health Activists (ASHAs), who are local female residents
from the village. ASHAs have an average of ten years of
formal education and are selected for this role by the vil-
lage Panchayat (a village based self-governance system)
and receive performance-based remuneration under In-
dia’s National Rural Health Mission program. On aver-
age, they work for two to three hours each day. Until
now they have primarily been deployed to provide ma-
ternal and child health services via household visits. This
suggests that this workforce can be trained to effectively
identify people at high risk and refer them appropriately
for medical care. In this study, the ASHA model is used
as a platform for the integrated delivery of cardiovascu-
lar disease risk factor screening.
Clinical decision support systems (CDSS)
In five systematic reviews on the effectiveness of CDSS,
approximately two-thirds of controlled studies have
demonstrated improvement in healthcare performance
[14-19]. The vast majority of high quality trials, however,
have been conducted in high income countries and have
targeted physicians and other healthcare workers with
high levels of training. The external validity of CDSS in
Low and Middle Income Country (LMIC) settings is un-
clear [20]. One promising strategy to increase the uptake
of CDSS in resource limited settings is through the use
of mobile devices (mobile phones, smartphones and tab-
lets). Given their increasing ubiquity, these devices rep-
resent one of the few hardware products available with
the potential to transform the delivery of essential
healthcare on a large scale. Research evidence to demon-
strate this, however, is still relatively nascent. Despite the
promise of an ‘m-health’ revolution in LMICs, a recent
comprehensive review concluded that the current evi-
dence for their effectiveness is fragmented and focused
Praveen et al. Implementation Science 2013, 8:137 Page 3 of 8
http://www.implementationscience.com/content/8/1/137on intermediary outcomes such as cost savings and im-
proved data quality [21].
SMARTHealth – mobile decision support development
To help address these research gaps, we developed a
novel comprehensive CDSS to facilitate Systematic Ap-
praisal Referral and Treatment of CVD risk in rural
India (SMARTHealth India). It has been designed for
use by ASHAs and PHC doctors. A single screening and
management algorithm was developed based on Indian
and international guidelines. World Health Organisa-
tion/International Society of Hypertension (WHO/ISHs)
region-specific risk charts are used to calculate a per-
son’s ten-year absolute CVD event risk. For management
recommendations, the Indian National Program for Pre-
vention and Control of Cancer, Diabetes Cardiovascular
and Stroke (NPCDCS) guidelines were programmed
[22].
The algorithm was programmed into an application
on a 7-inch tablet using Android 4.1 operating system.
Both English and local language versions (Telugu) were
developed. It was validated using a three-stage process
based on our previous work [23]. Stage 1 was an itera-
tive process where output from the algorithm was tested
using de-identified data from patients in a previous rural
Indian study and programming modifications were
made. Stage 2 involved independently programming the
algorithm into a statistical software package (SPSS v21.0,
Armonk, NY). Primary de-identified healthcare data
from 1,000 patients were imported into the CDSS and
the SPSS program. For all output variables, the correl-
ation (continuous variables) and agreement (categorical
variables) between the two programs were assessed. A
few minor coding errors in the CDSS were identified,
rectified and re-tested until perfect correlation/agree-
ment was achieved. Stage 3 involved user acceptance
testing and field testing with doctors and ASHAs in 11
villages and 3 PHCs. Detailed analyses of the develop-
ment and pilot phase will be published separately. Fol-
lowing the field testing, refinements were made to the
system to make it system-ready for trial implementation.
Research methods
Study objectives
The SMARTHealth India study will test whether a CDSS
will assist non-physician health workers and doctors in
making evidence based management decisions to lower
their patients’ CVD risks. The hypothesis is that a multi-
faceted intervention involving capacity strengthening of
primary healthcare doctors and non-physician healthcare
workers through use of a mobile device-based clinical
decision support system will result in improved BP con-
trol for individuals at high CVD event risk when com-
pared with usual healthcare.Study design
The intervention will be evaluated using a stepped-
wedge cluster randomised, controlled trial (cRCT) of
two years duration.
Study population
A total of 18 PHCs (3 villages per PHC) in West Godavari
District, Andhra Pradesh, will participate (see Statistical
considerations below). Patients will be eligible to participate
if they are residents of the study sites, are ≥40 years of age,
are classified at high CVD risk and are indicated for BP
lowering treatment based on WHO and NPCDCS
guidelines.
High CVD risk is defined as the presence of any of the
following:
1. Past history of CVD.
2. Estimated 10-year CVD risk ≥30%.
3. Estimated10-year CVD risk of 20% to 29% and a
Systolic BP >140 mmHg.
Risk will be calculated using WHO/ISH algorithms for
India.
Randomisation
Cluster randomisation will occur at the level of the
PHC. A total of 18 PHCs from West Godavari District
in Andhra Pradesh will be selected. To be eligible, all
PHCs must have at least one doctor regularly providing
services, and all doctors must be willing to participate in
the study. From the region serviced by each PHC, three
villages will be randomly selected (54 villages in total).
Six PHCs (18 villages) will be randomised to the inter-
vention over 3 time intervals or steps (Table 1). Per-
muted block randomisation will be centrally performed
at the George Institute in Hyderabad using a web-based
form stratified by PHC size. Outcome analyses will be
conducted blinded to intervention allocation.
A stepped-wedge design will ensure that every partici-
pating PHC and village receives the intervention (for at
least 6 months and an average of 12 months), while still
allowing an unbiased evaluation of the effectiveness of
the intervention compared to usual care.
Intervention components
SMARTHealth allows health workers to collect con-
sented patient information for screening and healthcare
purposes and process this information based on the al-
gorithm described above. The application then uploads
this information for a doctor to review using OpenMRS
– a secure, community-developed, open source, elec-
tronic medical record system platform. ASHAs can
make electronic referrals to the PHC doctor, and doctors
can notify the health worker via his/her tablet of the
Table 1 Stepped-wedge randomisation of the participating villages to the intervention group in three time intervals or
steps
Time interval
Number Month 0–6 Month 7–12 Month 13–18 Month 19–24
6 PHCs (18 villages) CONTROL INTERVENTION INTERVENTION INTERVENTION
6 PHCs (18 villages) CONTROL CONTROL INTERVENTION INTERVENTION
6 PHCs (18 villages) CONTROL CONTROL CONTROL INTERVENTION
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workflow and the key elements of the intervention pack-
age. The intervention comprises the following:
1. Equipment for ASHAs and PHC doctors to assess
and manage CVD risk using the CDSS application in
a 7-inch Smart Tablet. A backpack-sized kit, contain-
ing Smart Tablet, BP monitor, glucometer and other
management resources will be provided.
2. The application will also support ASHAs to promote
lifestyle advice for the determinants of high blood
pressure and CVD, in particular physical activity,
healthy diet and avoidance of tobacco and alcohol.
There will be no out-of-pocket costs for participants
accessing this service.GPRS/3G
Sanamobile system with d













6: Decision support is provided to PHC
physician.
Advice and treatment given to patient.





care to high risk
individuals seen at
PHC
Figure 1 Workflow and the key elements of the intervention package.3. Training and resource support to ASHAs and PHC
doctors. ASHAs will be provided with training in
taking a patient history and measurement of BP and
other CVD risk factors via the CDSS, provision of
lifestyle advice to lower CVD risk; referral of high
risk individuals and follow-up once seen by the doc-
tor. Doctors will similarly be trained in use of the
CDSS and additionally provided with training on
pharmacological management.
4. A shared electronic record functionality using Open
MRS and Sana to capture patient information via
Smart Tablet and securely send data to a centralised
server.
5. The doctors will use the electronic data transmitted
by the ASHAs and interpret the decision supportata 
rver
on-physician health worker
s risk factor information into
smartphone.
3: Point of care decision 
support provided to  
health worker  and 
advice given to patient.
High risk individuals
advised to visit PH Cclinic
4: Consenteddatafromhigh
risk individuals is uploaded to a
secure health record via the
Sana system
5: PHC physician reviews
data for referred high risk
individuals
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factors. The decision support is based on current
Indian national guidelines and will provide
recommendations for BP lowering, lipid lowering, or
anti‐platelet medications. The doctors will be
advised to prescribe medications from these drug
classes that are available on the essential medicine
list in primary healthcare facilities to minimise out
of pocket expenses.
6. A prompt system for follow-up of high risk individ-
uals by ASHAs and doctors.
7. Both ASHAs and physicians have a permitted
private practice allocation and will be remunerated
accordingly. This is actively encouraged by district
medical health officers and will ensure study
participation will not divert the ASHA or the PHC
doctor from their usual duties addressing other
health priorities for the population.
Control arm
During control periods, access to healthcare will con-
tinue as per usual practice without the ASHAs and PHC
doctors having access to the CDSS, associated tools, and
the training and support package.
Data collection
The study schema is outlined in Figure 2. Independent
data collection will be conducted by trained household
surveyors based on previous well-established and accept-
able methods [6,8-10,13]. Collection will occur on five
occasions for each village – at baseline, at each interim
time-interval (i.e., each ‘step,’ see Table 1), and at the end
of follow-up. This allows unbiased evaluation of effect-
iveness through comparison of ‘control periods’ (for18 PHCs
(3 villages per PHC)










Figure 2 SMARTHealth study schema.each village, the period between baseline and pre-
intervention) and ‘intervention periods’ (for each village,
the period between pre-intervention and end of follow-
up).
At baseline, a complete household survey (average of
approximately 1,000 households per village) will be per-
formed in each village. Trained field researchers will
conduct interviews and make physical measurements
using well-established methods [6]. In each household,
every consenting adult aged ≥40 years of age will be
assessed, and those at high risk of CVD will be identi-
fied, resulting in a census of all such individuals. Any in-
dividuals with extreme elevations of risk factors will be
referred immediately for treatment. At each subsequent
time point, data will be collected from a random inde-
pendent sample of 15% of people identified at the base-
line census as being at high risk (average of
approximately 50 people per village). These data are for
evaluation purposes only, and the ASHA and PHC doc-
tors will not have access to this information.
Primary outcomes
1. Difference in proportion of high risk individuals
(with or without CVD) who are achieving optimal
BP levels (systolic BP <140 mmHg) between the
intervention and control periods.
Secondary outcomes
1. Mean reduction in BP levels.
2. Change in other CVD risk factors, including body
mass index; current smoking; reported healthy
eating habits; and reported physical activity levels.Full baseline household survey 
(average ~1000 households per 
village) to identify all high-risk 
adults. 
Independent sample of 50 high-
risk individuals per village
Independent end of follow-up 
sample of 50 known high-risk 
participants (identified in 
baseline household survey) per
village
Independent sample of 50 
known high-risk participants 
(identified in baseline 
household survey) per village 
at each time-interval 
ontrol 
nths)
s at end 
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medicines.
4. Quality of life (using the EQ-5D).
5. CVD events (using hospitalisation data).
Statistical considerations
A total of 18 PHC clusters (with 3 villages per cluster)
progressively randomised by a third to the intervention
(Table 1) will provide >90% power (2α = 0.05) to detect
an absolute difference of 6% in the proportion of people
with optimal BP levels. This translates to an increase in
the proportion achieving optimal BP levels from 39%
(based on our previous data) to 45% and a mean systolic
BP difference of around 3 mmHg. These calculations
maximise the study power afforded by a stepped-wedge
design and assume an intraclass correlation coefficient
(ICC) of 0.03 (more conservative than the ICC of 0.01
previously observed in this population) and 5 time-
points for data collection. The mean village population
is approximately 4,000, with one-third aged ≥40 years.
Based on previous data from the region, approximately
23% of adults aged ≥40 years (approximately 300 indi-
viduals per village) are likely to be classified as being at
high risk, with around 35% of these having established
CVD [9]. Considering a conservative participation rate
at each survey, a PHC cluster size of 150 patients per
time point (approximately 50 per village) is anticipated
on the basis of the above calculation. Methods based on
mixed effects models as described by Hussey and
Hughes will be used to analyse intervention effectiveness
on primary and secondary outcomes, accounting for
outcome variable type, potential time effects, clustering
and stepped wedge design [24].
Economic and process evaluation
The economic evaluation will have a trial-based compo-
nent and a modelled evaluation of long-term costs and
outcomes. The intervention cost will be based on salar-
ies, training, equipment and other costs incurred with
implementation of the intervention. Trial-based data,
however, cannot capture costs and outcomes beyond the
trial. A decision-analytic model will enable long-term
cardiovascular morbidity, quality of life and survival to
be simulated. Cost-effectiveness will be calculated in
terms of incremental cost per quality adjusted life years
gained. This will better inform policy makers as to the
resource consequences of rolling out this program to
scale.
A detailed awareness of local contextual factors will be
critical to understanding the impact of the intervention
and any barriers to its implementation. The process
evaluation will be informed by behaviour change theory
[25], assessing how well the new system of service
provision fits within the usual processes of currentservice provision in the villages and PHCs centres. A
mixed methods approach to investigate why the inter-
vention strategy may or may not have been effective and
which intervention components were most influential
will be used. Three data sources will be used: de-
identified usage data from the tablet based system; pa-
tient and provider surveys; and semi-structured inter-
views with a purposive sample of participants and care
providers toward the end of study.
Ethical considerations
The study is approved by the Centre for Chronic Disease
Control Institutional Ethics Committee (IEC), New
Delhi and the University of Sydney Human Research
Ethics Committee (HREC), NSW, Sydney. It is also reg-
istered in the Clinical Trials Registry of India. The study
has also been discussed with each village Panchayat. In-
formed consent will be obtained from all participants
contributing data before the randomisation process. All
data collection and reporting will be compliant with na-
tional privacy law, and no report will allow an individual
participant to be identified. Data will be securely stored
at the George Institute Hyderabad. All study records and
documents will be stored for a minimum of seven years
from the end of the study or for a period as required by
any individual HREC.
Trial status
The study will be initiated with a household baseline
survey in all 54 villages by the fourth quarter of 2013.
Randomisation of PHCs and follow-up village surveys of
high risk individuals will continue until the first quarter
of 2016, followed by analysis and dissemination of the
findings in middle of 2016.
Discussion
SMARTHealth India focuses on a ‘real life’ implementa-
tion of a complex intervention. It represents a case study
into ‘Integrated Innovation’ [26], incorporating a sci-
ence/technology component (Smart Tablet, CDSS, and
cutting edge trial design), a social component (innova-
tive workforce strategies), and a business component (in-
tegration with existing health system infrastructure).
Despite great promise for m-health interventions to im-
prove access to effective healthcare, there remains con-
siderable uncertainty about how this can be successfully
achieved. These uncertainties pose substantial dilemmas
for health system planners, particularly in LMICs. This
project will rigorously explore the challenges of imple-
menting well-established evidence into practice.
Strengths and limitations
The strengths of the study are that it explores the chal-
lenges of implementing a complex intervention, taking
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sumer perspectives. The evidence generated thus has
substantial potential to inform decision-making for sys-
tem planners on a scalable solution to increasing access
to high quality primary healthcare for common chronic
conditions.
The main limitation is that it is conducted in one rural
region of one country, and the findings may not be
generalizable to elsewhere. Integrating the intervention with
the existing primary healthcare system, which is broadly
similar in all parts of India, will help to mitigate this and
enhance the relevance of the results across India and other
regions with similar health system structures. Another po-
tential limitation is that by using a stepped-wedge design,
secular changes in the region during the study period may
bias the outcomes. However, considering the study dur-
ation, time adjustment in the analysis, and recommenda-
tions by key stakeholders that access to the intervention be
provided to all centres, this design provides, on balance, the
most acceptable method to test the study hypothesis in a
rigorous but pragmatic manner.
Significance
The findings from this study are likely to advance locally
relevant knowledge on scaling up a strategy to overcome
entrenched inequities in access to effective healthcare
for under-served populations. Such approaches, if found
to be effective and cost-effective and combined with ef-
fective population-based strategies, have the potential to
positively impact the healthcare of millions of Indians
on a daily basis and will have wider applicability for
other LMICs.
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